

CIHR: Antimicrobial Resistance - Point of Care Diagnostics in Human Health Phase 2

Sponsor

Canadian Institutes of Health Research, the Antimicrobial Resistance Initiatives, under the scientific leadership of the Institute of Infection and Immunity and the Institute of Population and Public Health.

Description

The CIHR Antimicrobial resistance (AMR) initiative aligns with the research component of the existing [Federal Framework on AMR](#) [1], which aims to promote innovation through funding collaborative research and development efforts on antimicrobial resistance both domestically and internationally, as well as [Tackling Antimicrobial Resistance and Antimicrobial Use: A Pan-Canadian Framework for Action](#) [2].

Under the AMR initiative, CIHR has launched the Antimicrobial Resistance: Point of Care (POC) Diagnostics in Human Health program. [Phase 1](#) [3] aimed to advance innovative AMR point-of-care diagnostics closer to a stage of clinical readiness; [five teams were funded](#) [4]. CIHR is now launching a Phase 2 open competition, which aims to further accelerate development of technologies or tools that have passed the preliminary design developmental phase. You do not have to have been funded in Phase 1 to be eligible to apply to Phase 2.

The main goal of this funding opportunity is to further facilitate and improve the development of clinically relevant point-of-care diagnostic tools in AMR that will improve rational use of antibiotics and improve clinical management.

This funding opportunity will support projects relevant to any of the following research areas:

- Projects that have a human health focus at the patient or bedside level (adult and/or pediatric).
- Diagnostic tools that distinguish bacterial from viral infections (e.g. host biomarkers, multiplex, etc.) both qualitatively or quantitatively.
- Pathogen (bacteria, viruses, fungi, parasites)-specific diagnostics, providing information on susceptibility/resistance to antimicrobial agents.
- Diagnostic tools that permit at least one of the following:
 - a shorter time-to-result identification of specific infectious agent and their resistance profile;
 - an increased sensitivity and/or simplicity of test or allow for more minimally invasive specimen collection;

- a facilitated communication of results to healthcare provider or public health practitioner; and
- a rapid diagnostics for resource-limited settings.
- Evaluations of POC testing for AMR in different settings.
- Studies on feasibility, acceptability, change in policies for the introduction of POC tests for detecting resistance microbial pathogens.

Eligibility

This funding opportunity is open to all applicants, provided they meet all of the eligibility criteria and submit an application relevant to the objectives and relevant research areas. It is not a prerequisite to have Phase 1 funding in order to apply to Phase 2.

For an application to be eligible:

1. The Nominated Principal Applicant must be an [independent researcher](#) [5]
2. The Nominated Principal Applicant must be appointed at an eligible institution (See [Institutional Eligibility Requirements](#) [6] for eligibility process and associated timelines)
3. At least one additional Principal Applicant must be appointed at an eligible institution (See [Institutional Eligibility Requirements](#) [6] for eligibility process and associated timelines). This Principal Applicant must be an [independent researcher](#) [5].
4. An end-user (i.e. clinician, nurse, technician, patient, etc.) must be identified as the Knowledge User and must have a role in defining the usability of the point-of-care technology being developed.
5. Applications must include a minimum of 1:1 matching (cash or cash-equivalent) from [eligible partner\(s\)](#) [7].

Funding Availability

The total amount available for this funding opportunity is \$2,025,000, enough to fund approximately three grants.

Maximum Project Value

The maximum amount per grant is \$225,000 per year or a total of \$675,000 per grant.

Indirect Costs

0%

Project Duration

three years

Deadlines

If College-level review is required, your College will communicate its earlier internal deadlines.

Type	Date	Notes
Internal Deadline	Tuesday, August 14, 2018 - 11:59pm	PI to submit a copy of application, routing slip and signature pages along with a complete OR5 form to: research.h.services@uoguelph.ca
External Deadline	Tuesday, August 21, 2018 - 8:00pm	PI to complete Full Application, follow the instructions in the Grants – Application Guidelines [8] along with any additional instructions found below under “Specific Instructions” . [9] and submit using online application system ResearchNet . [10] All participants listed (other than Collaborators) will require a CIHR PIN [11].

Information For Co-applicants

If you need to meet a deadline set by the lead institution for this opportunity, please ensure that you provide the Office of Research with at least five days in advance of the lead institution's deadline to review the application, or your proposed component of the project. Please be in touch with the Office of Research (contact information below) ahead of the deadline if it looks like it will be difficult for you to submit all the required documentation on time (i.e. budget, proposal, OR-5 Form).

For Questions, please contact

CIHR Contact Centre

Telephone: 613-954-1968

Toll Free: 1-888-603-4178

Email: support@cihr-irsc.gc.ca [12]

Office of Research

Ornella McCarron, Grants Officer

Research Services Office

519-824-4120 x52832

omccarro@uoguelph.ca [13]

Alert Classifications **Category:**

Funding Opportunities and Sponsor News

Disciplines:

Health and Life Sciences

Source

URL: <https://www.uoguelph.ca/research/alerts/content/cihr-antimicrobial-resistance-point-care-diagnostics-human-health-phase-2>

Links

[1] <https://www.canada.ca/en/public-health/services/antibiotic-antimicrobial-resistance/antimicrobial-resistance-use-canada-federal-framework-action.html>

[2] <https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/tackling-antimicrobial-resistance-use-pan-canadian-framework-action.html>

[3] <https://www.researchnet-recherchenet.ca/rnr16/vwOpprtntyDtls.do?prog=2441&view=search&terms=point+of+care+diagnostics&incArc=true&type=EXACT&resultCount=25&next=1>

[4] http://webapps.cihr-irsc.gc.ca/cfdd/db_search?p_language=E&p_competition=201611ARF

[5] <http://www.cihr-irsc.gc.ca/e/34190.html#r6>

[6] <http://www.cihr-irsc.gc.ca/e/22630.html#F31>

[7] <https://www.researchnet-recherchenet.ca/rnr16/vwOpprtntyDtls.do?prog=2846&view=currentOpps&type=EXACT&resultCount=25&sort=program&next=1&all=1&masterList=true#ep>

[8] <http://www.cihr-irsc.gc.ca/e/50454.html>

[9] <http://www.researchnet-recherchenet.ca/rnr16/vwOpprtntyDtls.do?prog=2846&view=currentOpps&type=EXACT&resultCount=25&sort=program&next=1&all=1&masterList=true#eligibility>

[10] <http://www.researchnet-recherchenet.ca/rnr16/LoginServlet?language=E>

[11] <http://www.cihr-irsc.gc.ca/e/38201.html>

[12] <mailto:support@cihr-irsc.gc.ca>

[13] <mailto:omccarro@uoguelph.ca>